Micin vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
MICIN raised 10B+ yen (~$99M) through Series C; its Curon telemedicine platform serves 5,000+ Japan clinics; digital therapeutics and clinical development tools round out a multi-pillar health tech platform.
About
MICIN is a Tokyo-based healthcare technology company founded in 2015 that operates at the intersection of telemedicine, digital therapeutics, and clinical development. Its flagship platform, Curon, enables online medical consultations — allowing patients in Japan to book appointments, receive virtual consultations, pay, and receive prescription delivery entirely online. Launched in 2016, Curon is now used by more than 5,000 clinics and hospitals across Japan.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.